A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice

Table 3 Categorization of clinical outcomes (ADHD symptoms and functionality)—exploratory subgroup analysis (n = 304)

Pre-initiation of GXR treatment^a		Post-initiation of GXR treatment^b
	n	Improvement	No change	Worsening
General Physician Symptom Assessment, n (%)*^c
Improvement	172	130 (75.6)	2 (1.2)	0 (0.0)
No change	74	37 (50.0)	9 (12.2)	1 (1.4)
Worsening	54	44 (81.5)	2 (3.7)	3 (5.6)
General Physician Functional Assessment, n (%)^c
Homelife*
Improvement	132	102 (77.3)	4 (3.0)	1 (0.8)
No change	118	52 (44.1)	9 (7.6)	2 (1.7)
Worsening	48	34 (70.8)	9 (18.8)	1 (2.1)
School performance*
Improvement	161	111 (68.9)	3 (1.9)	0 (0.0)
No change	89	45 (50.6)	11 (12.4)	2 (2.2)
Worsening	44	33 (75.0)	5 (11.4)	2 (4.5)

Exploratory subgroup analysis in a subgroup of patients who had received prior pharmacotherapy for ADHD
ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended-release
^*P < 0.001, derived through extension of McNemar’s test (Bowker’s test)
^aOverall response to treatment regimen administered prior to GXR administration
^bThe best response registered while on treatment with GXR
^cPercentages were calculated using the corresponding categories under GXR treatment count as denominator; due to missing values, percentages in each category do not add up to 100%

ISSN: 1753-2000